Long considered a defensive stalwart in investment portfolios, UnitedHealth has faced substantial headwinds throughout 2025. The return of former CEO Stephen Hemsley has heralded a period of aggressive strategic repositioning. His response to significant share price depreciation involves a dual-pronged approach: withdrawing from unprofitable markets while simultaneously strengthening the company’s board. As legendary investor Warren Buffett capitalizes on this weakness to build a position, market participants are questioning whether the stock has found its floor or if profitability faces further compression.
Profitability Takes Precedence Over Expansion
A fundamental strategic shift is underway concerning UnitedHealth’s Medicare Advantage plans. The previous growth-at-all-costs model has been abandoned in favor of a sharp focus on margin improvement. In a decisive move, the corporation announced it will exit 109 U.S. counties and discontinue more than 100 additional plans in 2026.
While impacting hundreds of thousands of members, this consolidation is designed to enhance operational efficiency. Future operations will concentrate on regions where its subsidiary, Optum, maintains a robust network presence. This strategic pivot is a direct response to spiraling costs that have recently pressured financial results. To better navigate the complex regulatory landscape, the company has also enlisted Dr. Scott Gottlieb, the former head of the U.S. Food and Drug Administration, to join its board.
Operational Metrics Signal Significant Strain
The necessity for such a drastic restructuring is clearly illustrated by the third-quarter financial results. Despite reporting revenue growth, the company’s profitability metrics showed severe deterioration. The operating margin for the Optum Health segment experienced a dramatic collapse, falling to a mere 1 percent—a stark contrast to the 8.3 percent recorded during the same period last year.
Should investors sell immediately? Or is it worth buying Unitedhealth?
This precipitous decline is attributed to several converging factors:
* Elevated Utilization: Patient demand for medical services has substantially exceeded projections.
* Government Reductions: Public funding for these plans has been scaled back.
* Persistent Inflation: Rising operational expenses continue to erode revenue.
The Medical Care Ratio, a key metric comparing medical costs to premium income, remains a concern, hovering at a notably high level of nearly 90 percent.
A Vote of Confidence from Prominent Investors
Despite these operational challenges, a potential silver lining exists for contrarian investors. In a significant development during the second quarter, Warren Buffett’s Berkshire Hathaway acquired approximately 5 million shares, seizing the opportunity presented by the depressed stock price. Furthermore, CEO Stephen Hemsley demonstrated his own conviction by investing roughly $25 million of his personal capital into UnitedHealth shares—a powerful endorsement of the ongoing turnaround effort.
Having declined more than 41 percent since the start of the year, the stock is now trading well below its historical valuation ranges. Market analysts are beginning to see potential at the current price level of around 287 euros, especially given its significantly reduced price-to-earnings (P/E) ratio of 16. The effectiveness of this aggressive strategic overhaul will be critically assessed when the company releases its next quarterly figures in January 2026.
Ad
Unitedhealth Stock: Buy or Sell?! New Unitedhealth Analysis from February 7 delivers the answer:
The latest Unitedhealth figures speak for themselves: Urgent action needed for Unitedhealth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Unitedhealth: Buy or sell? Read more here...
